Data Supplement
- Supplemental Data -
Supplementary Table 1 - Previous studies that reported scaling fraction protein to original tissue in cirrhosis and their limitations.
Supplementary Table 2 - Demographic and clinical data for individual donors of control samples.
Supplementary Table 3 - Demographic and clinical data for individual donors of cirrhosis liver samples and Child-Pugh classification.
Supplementary Table 4 - NADPH-CYP450 reductase activity (Units mg-1 of liver tissue) in both homogenate and microsomal fractions from control and cirrhosis samples.
Supplementary Table 5 - Study design, doses, and demographic data from the clinical studies used for simulating alfentanil, metoprolol, and midazolam concentration- time profiles in cirrhosis populations.
Supplementary Table 6 - PBPK parameters for midazolam, metoprolol, alfentanil, and ethinylestradiol used for the simulations.
Supplementary Table 7 - Mean and standard deviation of protein concentrations (μg μL-1) of different fractions (microsomes, homogenate, cytosol) for each individual sample (normal and cirrhotic).
Supplementary Table 8 - Median protein content per gram tissue for each fraction in the control, mild, moderate, and severe cirrhosis groups without correction for the loss due to centrifugation.
Supplementary Table 9 - Physiological differences between healthy volunteers and patients with liver cirrhosis population within Simcyp Simulator V18.
Supplementary Figure 1 - Comparing current study MPPGL values for the control group corresponding to each patient age with the predicted MPPGL from the equation by (Barter, et al., 2008) with 95% confidence interval lines from the same study.
Supplementary References